個人積分：4分
文章編號：18215060
個人積分：48分
文章編號：18216966
http://www.marketwatch.com/story/ap-pharma-sinks-medicines-co-gains-2010-03-19?reflink=MW_news_stmp
"U.S. Food and Drug Administration has informed the company it will not approve APF350 for the treatment of chemotherapy-induced nausea until more supporting information is provided."
http://www.thestreet.com/story/10707025/1/ap-pharma-netlist-early-volume-plays.html?cm_ven=GOOGLEFI
"A.P. Pharma (APPA) dropped by $1.08, or 52.7%, to 97 cents after the Food and Drug Administration did not approve its experimental drug APF530 for the treatment of nausea and vomiting induced by chemotherapy. The FDA said it found deficiencies in A.P.'s manufacturing facilities, and that more supporting information is needed. Volume topped 9.61 million shares, compared to the 50-day average daily volume of 658,000, according to the Nasdaq."
都可以看到FDA說需要更多資訊，請問一般的case都是這樣嗎？
我的意思是，FDA沒核准新藥時都會說"需要更多資料"？
還是真的APPA只要後來提供足夠資料就會有機會過？
這才是賭博呀...
個人積分：4分
文章編號：18219296
個人積分：1528分
文章編號：18221373
個人積分：756分
文章編號：18222680
個人積分：136分
文章編號：18225624
個人積分：300分
文章編號：18344213
